Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Cash from Financing Activities (2017 - 2025)

Historic Cash from Financing Activities for Puma Biotechnology (PBYI) over the last 8 years, with Q3 2025 value amounting to -$11.3 million.

  • Puma Biotechnology's Cash from Financing Activities fell 133.24% to -$11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.2 million, marking a year-over-year decrease of 10074.17%. This contributed to the annual value of -$33.8 million for FY2024, which is N/A changed from last year.
  • Per Puma Biotechnology's latest filing, its Cash from Financing Activities stood at -$11.3 million for Q3 2025, which was down 133.24% from -$11.2 million recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's Cash from Financing Activities peaked at $9.8 million during Q1 2022, and registered a low of -$31.9 million during Q3 2021.
  • For the 4-year period, Puma Biotechnology's Cash from Financing Activities averaged around -$7.9 million, with its median value being -$11.2 million (2025).
  • As far as peak fluctuations go, Puma Biotechnology's Cash from Financing Activities plummeted by 7435348.84% in 2021, and later skyrocketed by 12165000.0% in 2022.
  • Over the past 4 years, Puma Biotechnology's Cash from Financing Activities (Quarter) stood at -$2000.0 in 2021, then soared by 121650.0% to $2.4 million in 2022, then tumbled by 566.1% to -$11.3 million in 2024, then dropped by 0.01% to -$11.3 million in 2025.
  • Its last three reported values are -$11.3 million in Q3 2025, -$11.2 million for Q2 2025, and -$11.3 million during Q1 2025.